Brind.

Akero Therapeutics conducted the HARMONY clinical trial, showing that EFX reduces fibrosis in MASH patients.

1 report, 1 independent Updated Aug 15

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Harmony mash

Keep exploring

The entities involved

Harmony
Italian record label
- José Raúl Mulino addressed leaders at the United Nations General Assembly on September 25, while Panama continues its work under the Harmony with Nature program.Fri 15:52
mash
fast genome and metagenome distance estimation using MinHash
- Wave Life Sciences is developing WVE-007, an investigational GalNAc-siRNA product, for MASH indications.Wed 12:44

Coverage

Newest first; wire copies grouped

Aug 15GlobeNewswireAkero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH Results sup